Mutational profile of papillary thyroid carcinoma in an endemic goiter region of North India

George, Nelson; Agarwal, Amit; Kumari, Niraj; Agarwal, Sarita; Krisnani, Narendra; Gupta, Sushil K.

doi:10.4103/ijem.ijem_441_17

Cited by 9 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have also shown BRAF V600E mutation in 46% of PTC. Our finding has an intermediate position between Mediterranean countries and North American and some Far East countries [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40] (Table 6). Some studies have close results to ours [28,29,30,35,36,38,39].…”

Section: Plos Onementioning

confidence: 99%

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates

et al. 2020

View full text Add to dashboard Cite

Background Papillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasm comprising 80-90% of all thyroid malignancies. Molecular changes in thyroid follicular cells are likely associated with the development of PTC. Mutations in serine/threonine-protein kinase (BRAF) and Rat sarcoma viral oncogene homolog (RAS) are commonly seen in PTC. Methods In total, 90 cases of PTC are randomly selected from archive paraffin blocks and 10μm sections were cut and processed for DNA extraction. BRAF V600E mutation and 8 types of KRAS mutations were investigated using Real Time PCR. Results BRAF V600E mutation was identified in 46% of PTC while KRAS mutations were seen in 11% of PTC. There was significant correlation between BRAF V600E mutation and PTC larger than 5cm in diameter, positive surgical margin and lymph node metastasis. BRAF V600E mutation was significantly higher in patients with less than 55-year of age than those more than 55-year of age. BRAF V600E mutation was significantly higher in patients with family history of thyroid cancer than those without. There was no significant difference in BRAF V600E mutation between males and females, PTC classic and follicular variants, unifocal and multifocal PTC. There was a significant higher percentage of BRAF V600E mutation in classic PTC than papillary microcarcinoma variant. There was no significant age, gender, histologic type, tumor size, lymph node metastasis, tumor focality, and surgical margin status differences between KRAS mutated and non-mutated PTC.

show abstract

Section: Plos Onementioning

confidence: 99%

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This result seems to be similar to a study conducted in India, which reported RAS mutation in 20% of the patients. 33 Lower rate of RAS mutation was found in Saudi Arabia, in which the rate of RAS mutation was 6.1%. 34 Among the three homologous isoforms, NRAS was the most frequent mutation displayed in thyroid nodules.…”

Section: Discussionmentioning

confidence: 96%

Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital

Harahap,

Subekti,

Panigoro

et al. 2023

TACG

View full text Add to dashboard Cite

Introduction BRAF V600E and RAS mutations are the most common gene mutations in papillary thyroid carcinoma (PTC) that may be correlated with its biological behavior. There are still limited data about BRAF V600E and RAS mutations in Indonesia. This study aims to determine the prevalence of BRAF V600E and RAS mutations, and their association with clinicopathologic characteristics. Methods Patients who had total thyroidectomy from 2019 to 2021 and those who met our study criteria underwent PCR and DNA sequencing analysis for BRAF V600E, BRAF K601E, exon 2 and 3 of NRAS, HRAS , and KRAS . Analyses were performed to determine the associations of BRAF V600E and RAS mutations with clinicopathologic characteristics. Results Of 172 PTC patients, BRAF V600E mutation was observed in 37.8% of the patients and RAS mutations were found in 21.5%. One patient harbored BRAF K601E mutation. There was a significant association of BRAF V600E with a high-stage (p = 0.033, OR: 3.279; 95% CI: 1.048–10.259), tall-cell variants (p ≤0.001, OR: 41.143; 95% CI: 11.979–141.308), non-encapsulated (p = 0.001, OR: 4.176; 95% CI: 2.008–8.685), lymphovascular invasion (p = 0.043, OR: 1.912; 95% CI: 1.018–3.592), extrathyroidal extension (p = <0.001, OR: 3.983; 95% CI: 1.970–8.054), and lymph node metastasis (p = 0.009, OR: 2.301; 95% CI: 1.224–4.326). Follicular variant (p = 0.001, OR: 7.011; 95% CI: 2.690–18.268), encapsulated (p = 0.017, OR: 2.433; 95% CI: 1.161–5.100), and absent of extrathyroidal extension (p = 0.033, OR: 2.890; 95% CI: 1.052–7.940) were associated with RAS mutations. Conclusion A significant association between BRAF V600E mutation and high clinical stage, tall-cell variants, non-encapsulated morphology, lymphovascular invasion, extrathyroidal extension, and lymph node metastasis in PTC was observed. RAS mutations were associated with the follicular variant, encapsulated tumor, and no extrathyroidal extension. HRAS -mutated PTC frequently exhibited tumor multifocality.

show abstract

“…Genetic studies looking into their role in ACS are scanty, especially in the Indian population [ 28 ]. In this context, we set out to study the prevalence and biological/clinical significance of these somatic mutations in our study population.…”

Section: Discussionmentioning

confidence: 99%

Is there adenoma-carcinoma sequence between benign adenoma and papillary cancer of thyroid: A genomic linkage study

Bangaraiahgari

Panchangam²,

Puthenveetil

et al. 2020

Annals of Medicine and Surgery

View full text Add to dashboard Cite

Mutational profile of papillary thyroid carcinoma in an endemic goiter region of North India

Cited by 9 publications

References 37 publications

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates

Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital

Is there adenoma-carcinoma sequence between benign adenoma and papillary cancer of thyroid: A genomic linkage study

Contact Info

Product

Resources

About